AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Interpretation of the T66I and G118R mutations in integrase in HIV-2View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Major protease resistance in West African HIV-1 subtypes is associated with novel protease mutations and accelerated gag evolution during second-line ARTView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Evaluation of the virological efficacy of switching to dolutegravir-based tritherapy in patients followed under real-life conditions in Abidjan, Côte d'IvoireView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Resistance analysis of pre- treatment NS3 and NS5A variants in HCV genotype 1a, 1b and 3a infected patients in CroatiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Using social media to improve follow-up and routine checks on newly diagnosed young people living with HIV and their adherence to Antiretroviral TherapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Changes in the HIV-1 3'- polypurine tract in patients failing dolutegravir in BrazilView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Analysis of mutational history of multi-drug resistant genotypes with a mutagenetic tree modelView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Predictors of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settingsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Comparison of Markers of Inflammation and Associated Baseline Variables in Virologically Suppressed Participants in the TANGO Study at Week 144View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Temporal trend of drug- resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individualsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022HIV reservoir quantification by combining total HIV-1 DNA assay and intact proviral DNA assay (IPDA) in one triplex digital PCR reactionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Reaching the 95-95-95 targets will not eliminate HIV transmission in 2030 among individuals born in sub-Saharan Africa residing in the NetherlandsView Abstract
